Basal insulin requirements on continuous subcutaneous insulin infusion during the first 12 months after diagnosis of type 1 diabetes mellitus

Journal of Diabetes Science and Technology

Volumn 4, Issue 3, 2010, Pages 610-614

  Ramchandani, Neesha ^a   Ellis, MaryKristine ^a   Jain, Shobhit ^b   Bhandari, Sonal ^a   Anhalt, Henry ^c   Maclaren, Noel K ^d   Ten, Svetlana ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c Animas Corp   (United States)

^d BioSeek Endocrine Clinics   (United States)

Author keywords

Basal insulin production; Basal insulin requirements; Continuous subcutaneous insulin infusion; Insulin pump; Type 1 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; BASAL INSULIN; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; BODY MASS; CHILD; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MALE; PRESCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; YOUNG ADULT;

EID: 78349238231     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400315     Document Type: Article

References (21)

1. Ferrannini E, Pilo A. Pattern of insulin delivery after intravenous glucose injection in man and its relation to plasma glucose disappearance. J Clin Invest. 1979;64(1):243-54. (Pubitemid 9216540)
2. Gardner DG, Shoback D. Greenspan's basic and clinical endocrinology. 8th ed. New York: McGraw Hill; 2007.
3. Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams textbook of endocrinology. 11th ed. St. Louis: Saunders; 2008.
4. Brunton L, Parker K, Blumenthal D, Buxton I. Goodman and Gilman's manual of pharmacology and therapeutics. New York: McGraw-Hill; 2008.
5. Degroot L, Jameson JL. Endocrinology: volume 1. 5th ed. Philadelphia: Saunders; 2005.
6. Ramchandani N, Ten S, Anhalt H, Sinha S, Ching J, Finkelstein A, Maclaren NK. Insulin pump therapy from the time of diagnosis of type 1 diabetes. Diabetes Technol Ther. 2006;8(6):663-70. (Pubitemid 44871496)
7. Bolli GB. Insulin treatment in type 1 diabetes. Endocr Pract. 2006;12 Suppl 1:105-9. (Pubitemid 44963623)
8. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27(7):1554-8. (Pubitemid 38857425)
9. Renard E. Intensive insulin therapy today: 'basal-bolus' using multiple daily injections or CSII? Diabetes Metab. 2005;31(4 Pt 2):4S40-4.
10. Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basalprandial insulin therapy. Diabetes Res Clin Pract. 2006;73(1):35-40. (Pubitemid 44226296)
11. Shalitin S, Phillip M. The use of insulin pump therapy in the pediatric age group. Horm Res. 2008;70(1):14-21. (Pubitemid 351919797)
12. Pańkowska E, Szypowska A, Lipka M. Basal insulin and total daily insulin dose in children with type 1 diabetes using insulin pumps. Pediatr Diabetes. 2008; 9(3 Pt 1):208-13.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
14. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulindependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125(2):177-88.
15. Boland, EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care. 1999;22(11):1779-84. (Pubitemid 29521861)
16. Danne T, Mortensen HB, Hougaard P, Lynggaard H, Aanstoot HJ, Chiarelli F, Daneman D, Dorchy H, Garandeau P, Greene SA, Hoey H, Holl RW, Kaprio EA, Kocova M, Martul P, Matsuura N, Robertson KJ, Schoenle EJ, Søvik O, Swift PG, Tsou RM, Vanelli M, Aman J, Hvidøre Study Group on Childhood Diabetes. Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidøre Study Group. Diabetes Care. 2001:24(8):1342-7. (Pubitemid 33716418)
17. Potti LG, Haines ST. Continuous subcutaneous insulin infusion therapy: a primer on insulin pumps. J Am Pharm Assoc. 2009;49(1):e1-13.
18. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-9.
19. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009;169(14):1307-16.
20. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997;20(9):1353-6. (Pubitemid 27366805)
21. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31(10):1927-32.